Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

# Final Appraisal Recommendation

**Advice number: 1122 – June 2022**

## Bevacizumab (Avastin®) 25 mg/ml concentrate for solution for infusion

## Resubmission by Roche Products Ltd

### Recommendation of the All Wales Medicines Strategy Group

**Bevacizumab (Avastin®) is recommended as an option for restricted use within NHS Wales for use in combination with paclitaxel and cisplatin for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.**

**Bevacizumab (Avastin®) is not recommended for use within NHS Wales for use in combination with paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.**

**This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent to or lower than the PAS price.**

**Bevacizumab should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.**

**Additional note(s):**

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG did not consider bevacizumab (Avastin®) as an orphan or ultra-orphan equivalent medicine as the criteria in the AWMSG appraisal process for a medicine for a rare disease were not met. The full population of the licensed indication exceeds the threshold ≤ 1 in 2,000 people in Wales (or the UK).
- AWMSG did not consider that the AWMSG criteria for appraising life extending, end-of-life medicines applied to bevacizumab (Avastin®) for the indication under consideration; the incremental cost-effectiveness ratio (ICER) estimated did not exceed £30,000 per quality-adjusted life-year (QALY) gained.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5044), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.